Results 151 to 160 of about 61,737 (200)

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Lancet, The, 2020
Summary Background Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir–ritonavir, and ribavirin for treating patients with ...
Kwok-Cheung Lung, Tom Wai-Hin Chung, Hoi-Ping Shum   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Synthesis and characterization of gelatin/lignin hydrogels as quick release drug carriers for Ribavirin.

International Journal of Biological Macromolecules, 2022
In this study, hydrogels based on gelatin and lignin were fabricated as efficient drug carriers for Ribavirin. The obtained hydrogels were characterized by scanning electron microscopy (SEM), ATR-FTIR spectroscopy, differential scanning calorimetry (DSC),
Elahe Chiani, A. Beaucamp, Y. Hamzeh, M. Azadfallah, A. V. Thanusha, M. Collins   +5 more
semanticscholar   +1 more source

Ribavirin

Drug Intelligence & Clinical Pharmacy, 1984
Despite the plethora of antibiotics available for the treatment of bacterial infections, very few agents have been developed to treat viral diseases. Ribavirin (Virazole) is a triazole nucleoside antiviral agent that produces selective antiviral effects against a broad spectrum of RNA and DNA viruses.
Roberts A. Smith, Peter Canonico
openaire   +3 more sources

Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

New England Journal of Medicine, 2014
Jordan Feld, Ola Weiland
exaly   +2 more sources

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

New England Journal of Medicine, 2014
Stefan Zeuzem, Alessandra Mangia, Robert Flisiak   +2 more
exaly   +2 more sources

Ribavirin

Pediatrics, 1987
Immunization has proved to be the most effective way of controlling viral diseases, and the development of antiviral drugs has lagged behind the development of antibacterial agents. Many of the early antiviral agents were DNA nucleoside analogs such as idoxuridine, cytarabine, and vidarabine, which competitively inhibited replication of DNA viruses ...
openaire   +4 more sources

ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

New England Journal of Medicine, 2014
BACKGROUND Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis.
Kosh Agarwal, Heiner Wedemeyer, Thomas Berg   +2 more
exaly   +2 more sources

Ribavirin Analogs

Clinics in Liver Disease, 2009
Ribavirin is ineffective against hepatitis C virus as mono-therapy but is critical in attaining both early virologic response and sustained virologic response when combined with pegylated interferon. Ribavirin has significant dose-limiting toxicities, the most important of which is hemolytic anemia.
William W, Shields, Paul J, Pockros
openaire   +2 more sources

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

New England Journal of Medicine, 2009
Mitchell N Davis, Mark S Sulkowski
exaly   +2 more sources

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Lancet, The, 2014
Eric Lawitz, Mark S Sulkowski, Zobair M Younossi   +2 more
exaly   +2 more sources